2025 Highlights with Dr. Mita Manna: From Insight to Impact

Dr. Mitta Manna reviews key 2025 updates across HER2-positive, triple-negative, and HR+ metastatic breast cancer, highlighting antibody–drug conjugates, biomarker-driven therapies, and the shift toward escalation and de-escalation strategies guided by patient selection and consensus recommendations.